Association of discovered novel SNPs of FGFR2 and MAP3K1 genes from next-generation sequencing with the prognosis of hormone receptor-positive early breast cancer patients.

e12054Background: We and other investigators have demonstrated that CYP19TTTA repeat polymorphism, MAP3K1 rs889312, FGFR2 rs2981582, ABCB1 rs2032582, and TOX3 rs3803662 are associated with the prognosis of hormone receptor (HR)-positive early breast cancer patients. In this study, we assessed whether undiscovered single nucleotide polymorphisms (SNPs) of CYP19A1, MAP3K1, FGFR2, ABCB1, and TOX3are associated with clinical outcome of these patients. Methods: Using next-generation sequencing (NGS), we performed target region re-sequencing to analyze unidentified SNPs located in the candidate genes of CYP19A1, MAP3K1, FGFR2, ABCB1, and TOX3 in 84 HR+ early breast cancer patients with negative or 1 to 3 lymph nodal (LN) metastases. Among them, 74 (88.1%) with grade 1-2, 15 (17.9%) with HER2, and 16 (19.0%) with positive LN. The multivariate-adjusted hazard ratio of overall survival (OS) associated with the individual genotypes was assessed after adjusting for age, tumor size, tumor grade, HER2 status, and chem...